Partner. Advocate. Friend. At the MPN Research Foundation, we’re committed to standing with you in the fight against polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – the group of blood cancers collectively known as myeloproliferative neoplasms.
It is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).Read More
The American Society of Hematology presented Emmanuelle PasseguÃ©, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology.Read More
PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.Learn about PMF
Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.Learn about ET
The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.Learn about PV
Learn about MF patient Ryan Tellini and his journey with Interferon.Meet Ryan Tellini's Journey with Interferon
Meet ET patient, Jessica Harshbarger from Chicago, ILAge: 42 Meet Jessica Harshbarger
Juan Alderete, PV 06
By supporting MPN Research Foundation, you're also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.